Cancer immunotherapy has long been used in the treatment of metastatic melanoma, and
an anti-CTLA-4 monoclonal antibody treatment has recently been approved by the US Food
and Drug Administration. Targeted therapies such as small molecule kinase inhibitors
targeting deregulated mitogen-activated protein kinase (MAPK) signaling have markedly
improved melanoma control in up to 50% of metastatic disease patients and have likewise
been recently approved. Combination therapies for melanoma have been proposed as a …